The Harbor Health Care ETF returned 15.30% in the second quarter of 2026, led by strong gains in biotechnology stocks fueled by clinical data and merger activity. Pharmaceutical stocks lagged due to the ETF's lower exposure to Eli Lilly, a major benchmark component. Looking ahead to Q3, the outlook for mergers and acquisitions in biopharma is even more positive, suggesting continued potential growth in this sector.
Eli Lilly (LLY) trades at USD 1,147.39 with a 1-day gain of 0.85% as of Sep 15, 2026 15:21 WIB on Pluang. The Harbor Health Care ETF's Q2 2026 return of 15.30% contrasts with its lower exposure to Eli Lilly, a major benchmark stock. This dynamic highlights the ETF's focus on biotechnology stocks, which drove its strong quarterly performance.
At the Veeva R&D and Quality Summit in Boston, leading biopharma companies like Eli Lilly, Pfizer, and Sanofi shared innovations in AI, cloud platforms, and connected trials to accelerate drug development and improve quality. Highlights include Eli L...
Novo Nordisk is rated as a Buy compared to Eli Lilly because it trades at a significant valuation discount of about 26% to its big pharma peers despite having similar growth rates and a strong dividend yield. The stock is priced at roughly 11.2 times...
Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...
Eli Lilly is rapidly growing its obesity and diabetes treatment portfolio, with its tirzepatide-based drugs Mounjaro and Zepbound generating nearly $15 billion in revenue and showing strong year-over-year growth of 91% and 46%, respectively. This gro...
Eli Lilly's most profitable stock entry points were during less hyped events like the 2008 ImClone acquisition and the 2014 Trulicity approval, yielding returns over 2,000%. In contrast, buying at the peaks of hype around blockbuster drugs Mounjaro a...
